Hye Jung Park1, Jung-Won Park2, Sae Hoon Kim3, So-Yun Choi4, Hee-Kyoo Kim5, Chang-Gyu Jung6, Min-Suk Yang7, Dong Yoon Kang8, Min-Kyoung Cho8, Hyouk-Soo Kwon9, Hye-Ryun Kang8,10, Yong Won Lee11. 1. Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine , Seoul, Republic of Korea. 2. Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine , Seoul, Republic of Korea. 3. Department of Internal Medicine, Seoul National University Bundang Hospital , Seongnam, Republic of Korea. 4. Department of Pediatrics, Inje University Haeundae Paik Hospital , Busan, Republic of Korea. 5. Department of Internal Medicine, Kosin University College of Medicine , Busan, Republic of Korea. 6. Department of Internal Medicine, Keimyung University Dongsan Medical Center , Daegu, Republic of Korea. 7. Department of Internal Medicine, SMG-SNU Boramae Medical Center , Seoul, Republic of Korea. 8. Drug Safety Monitoring Center, Seoul National University Hospital , Seoul, Republic of Korea. 9. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul, Republic of Korea. 10. Department of Internal Medicine, Seoul National University Hospital , Seoul, Republic of Korea. 11. Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine , Incheon, Republic of Korea.
Abstract
BACKGROUND: The human leukocyte antigen (HLA)-B*13:01 was reported as an important risk factor for dapsone hypersensitivity syndrome (DHS) in Chinese and Thai populations. RESEARCH DESIGN AND METHODS: From the Korean nationwide registry, seven subjects with previous DHS were included. Their HLA allele/phenotype frequencies were compared with 8 dapsone-tolerant subjects recruited from a single institution, and general population (n = 485) in Korea. The authors also performed a meta-analysis with these data using previous Chinese and Thai studies. RESULTS: Among the seven DHS subjects, 85.7% presented with the HLA-B*13:01 allele. The HLA-C*03:04, HLA-DRB1*12:02 (both in linkage disequilibrium with HLA-B*13:01), and HLA-A*02:01 alleles were also presented in 85.7%, 71.4%, and 71.4%, respectively. Subjects with HLA-B*13:01 were susceptible to developing DHS compared to dapsone-tolerant controls (odds ratio [OR]: 73.667) and the Korean general population (OR: 139.500). HLA-C*03:04 (OR: 40.935), HLA-DRB*12:02 (OR: 36.613), and HLA-A*02:01 (OR: 5.862) showed similar results. In meta-analysis, HLA-B*13:01 was associated with dapsone-induced hypersensitivity (overall OR: 42.692), and subgroup analyses according to the control types demonstrated similar results (OR:43.694 and 41.866, respectively). CONCLUSIONS: Similar to previous Asian population studies, HLA-B*13:01 is significantly associated with the risk of DHS in Korea. These associations may be useful for preventing DHS and improving drug safety.
BACKGROUND: The human leukocyte antigen (HLA)-B*13:01 was reported as an important risk factor for dapsonehypersensitivity syndrome (DHS) in Chinese and Thai populations. RESEARCH DESIGN AND METHODS: From the Korean nationwide registry, seven subjects with previous DHS were included. Their HLA allele/phenotype frequencies were compared with 8 dapsone-tolerant subjects recruited from a single institution, and general population (n = 485) in Korea. The authors also performed a meta-analysis with these data using previous Chinese and Thai studies. RESULTS: Among the seven DHS subjects, 85.7% presented with the HLA-B*13:01 allele. The HLA-C*03:04, HLA-DRB1*12:02 (both in linkage disequilibrium with HLA-B*13:01), and HLA-A*02:01 alleles were also presented in 85.7%, 71.4%, and 71.4%, respectively. Subjects with HLA-B*13:01 were susceptible to developing DHS compared to dapsone-tolerant controls (odds ratio [OR]: 73.667) and the Korean general population (OR: 139.500). HLA-C*03:04 (OR: 40.935), HLA-DRB*12:02 (OR: 36.613), and HLA-A*02:01 (OR: 5.862) showed similar results. In meta-analysis, HLA-B*13:01 was associated with dapsone-induced hypersensitivity (overall OR: 42.692), and subgroup analyses according to the control types demonstrated similar results (OR:43.694 and 41.866, respectively). CONCLUSIONS: Similar to previous Asian population studies, HLA-B*13:01 is significantly associated with the risk of DHS in Korea. These associations may be useful for preventing DHS and improving drug safety.
Entities:
Keywords:
Dapsone; HLA-B*13:01; human leukocyte antigen; hypersensitivity syndrome